Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

Author： Fetterly Gerald   Owen Joel   Stuyckens Kim   Passarell Julie   Zannikos Peter   Soto-Matos Arturo   Izquierdo Miguel   Perez-Ruixo Juan  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.62, Iss.1, 2008-06, pp. : 135-147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

By Beumer Jan   Rademaker-Lakhai Jeany   Rosing Hilde   Hillebrand Michel   Bosch Tessa   Lopez-Lazaro Luis   Schellens Jan   Beijnen Jos  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 825-837

Springer Publishing Company

Access to resources Recommend Favorite

Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma

By Schöffski Patrick   Wolter Pascal   Clement Paul   Sciot Raf   De Wever Ivo   Wozniak Agnieszka   Stefan Cristiana   Dumez Herlinde  

Future Oncology, Vol. 3, Iss. 4, 2007-08 ,pp. : 381-392

Future Medicine

Access to resources Recommend Favorite

Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin): An example of potential problems for extrapolation of active drug concentrations from in vitro studies

By Tognon Gianluca   Frapolli Roberta   Zaffaroni Marco   Erba Eugenio   Zucchetti Massimo   Faircloth Glynn   D’Incalci Maurizio  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 89-90

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of Yondelis(TM) (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

By Twelves C.   Hoekman K.   Bowman A.   Vermorken J.B.   Anthoney A.   Smyth J.   van Kesteren C.   Beijnen J.H.   Uiters J.   Wanders J.   Gomez J.   Guzman C.   Jimeno J.   Hanauske A.   for the New Drug Development Group of the EORTC  

European Journal of Cancer, Vol. 39, Iss. 13, 2003-09 ,pp. : 1842-1851

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia

By Hsyu Poe-Hirr   Mould Diane   Upton Richard   Amantea Michael  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 209-218

Springer Publishing Company

Access to resources Recommend Favorite